A Safety and Tolerability Study of BPR-30221616 Injection in Healthy Subjects

NCT06760455 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: BPR-30221616 Injection
DRUG: Sodium Chloride Injection

Sponsor

Chengdu Brilliant Pharmaceutical Co., Ltd.